Leerink cuts Regeneron stock price target to $762 from $880
Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...
ENDPOINTS NEWS3d
Ex­clu­sive: Leerink builds health­care M&A team, poach­ing deal­mak­ers from ri­vals
In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...